Levi & Korsinsky Reminds Park Ha Biological Technology Co. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 28, 2026

BYAH shares collapsed ~93% on July 8, 2025 (down $38.02 to close at $2.99), wiping out more than $1B in market cap, and a securities class action has now been filed over alleged omissions tied to a promotional/pump-and-dump scheme and a reported <5% public float. The complaint alleges CFO/director Xiaoyan Zhu signed the Dec. 27, 2024 registration statement, which cited franchise fee revenue of $551.97k (6 months ended Apr. 30, 2024) and disclosed a 93% gross profit margin while allegedly failing to warn of manipulation risks. Lead plaintiff deadline is Sept. 28, 2026, and the case could increase legal overhang for BYAH and personally involve signatory executives/directors if omissions are proven.

Analysis

This is an idiosyncratic governance/liquidity event, not a demand-side read-through for beauty or China consumer demand. The real market mechanism is that a damaged low-float issuer loses access to cheap equity capital: future financing, if any, likely comes with deeper discounts, warrants, and even more dilution, which can keep the equity in a permanent bidless state. That also raises the odds of reverse splits and exchange-compliance risk, which matters more than the lawsuit itself for holders over the next 6-18 months.

Second-order, the event should widen the valuation gap between promotional microcaps and legitimate small-cap consumer names. Any peer that trades on narrative rather than audited cash flow is now more vulnerable to skepticism and lower retail participation, especially if it has a similarly concentrated float or aggressive social-media distribution. There is no obvious read-through to large-cap cosmetics or to SO/IVSBF; this is about the market repricing of float manipulation risk, not industry fundamentals.

The headline risk is mostly spent after the collapse, so the incremental downside from the class-action headline is likely limited unless it triggers a regulatory follow-on, a delisting notice, or borrow-driven forced selling. The contrarian view is that the stock may already discount a near-worst-case legal outcome, so fresh shorting into weakness is lower quality than shorting any reflexive squeeze. What would falsify the bearish thesis is a clean audited filing, improved disclosure around share issuance/float, or a regulatory finding that contradicts the alleged promotional scheme.

Key Decisions for Investors

• Avoid initiating longs in BYAH; treat it as a litigation/float-risk trap with poor liquidity and high gap risk over the next 1-3 months.
• If borrow is available and spreads are tradable, short any post-news relief rally in BYAH into the $3.50-$4.50 zone with a tight stop above the prior dislocation area; risk/reward is asymmetric only on rebounds, not on current weakness.
• Set an alert for SEC/exchange actions, reverse-split announcements, or any revised float/disclosure language over the next 30-90 days; those are the real catalysts for another leg lower.
• Use this as a screening trigger to underweight or avoid other low-float, retail-promoted U.S.-listed microcaps with offshore operating structures; the second-order selloff risk is in the basket, not just BYAH.
• No direct pair is attractive here; if you need a cleaner expression, prefer cash over forcing a sector pair, since the event is company-specific rather than a broad consumer or China demand signal.